With a skilled research team and years of experience in antibodies-drug conjugates (ADCs) development and production, BOC Sciences' ADCs manufacturing platform provides comprehensive payloads for your ADC projects and promotes clinical trials' advancement. Our highly skilled Ph.D. and M.S. synthetic chemists will help solve the payload development challenges you encounter during research, from biological to chemical payload development.
Antibodies-Drug conjugates (ADCs) represent a new class of cancer therapeutics, and their design involves tumor-specific antibodies, linkers, and cytotoxic payloads. Cytotoxins are part of the tumor-killing effect. Mechanistically, after the entrance of ADC to cells, cytotoxins are responsible for inducing target cell death. Therefore, the toxicity and physicochemical properties of cytotoxins directly affect the efficacy of ADC in tumor elimination. Thus, the cytotoxin used for conjugation should have a precise action mechanism, small molecular weight, high cytotoxicity, and can keep anti-tumor activity after chemically conjugated with antibodies.
Fig. 1. Structure of ADCs (Pharmacology & Therapeutics. 2021; 107917).
Clinically approved chemotherapeutics with known clinical profiles like doxorubicin, methotrexate, and 5-fluorouracil were commonly used as payloads in ADCs. The current generation of cytotoxic payloads falls into two mechanistic classes: those that target DNA and cause it damage and those that target microtubule polymerization. In order to support the efficacy of ADC through intracellular biological processes, antibodies, cytotoxic payloads, linkers, and conjugation methods need to be considered during the construction of ADC. BOC Sciences provides various cytotoxic payloads and create a series of ADCs of different payloads to support research screening. Nevertheless, we also offer payload linkers to our customers and enable independent research.
As a leading company in the field of antibodies-drug conjugates, BOC Sciences is able to provide biological payloads customization services such as protein toxin and enzyme toxin development. Our employees rely on advanced technology and knowledge to provide you with the most comprehensive and advanced biological payload development services.
BOC Sciences offers the types of chemical payload development, including microtubule inhibitors development, DNA inhibitors development, DNA topoisomerase inhibitors development, and RNA polymerase inhibitors development. Our complete technical platform and professional technical personnel ensure the reliability and accuracy of all developed products.
References